# Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

> **NCT02354170** · PHASE2 · COMPLETED · sponsor: **Roger Goldberg, M.D., MBA** · enrollment: 16 (actual)

## Conditions studied

- Central Serous Chorioretinopathy

## Interventions

- **DRUG:** Mifepristone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02354170
- **Lead sponsor:** Roger Goldberg, M.D., MBA
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-04-27
- **Final completion:** 2017-04-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354170, "Short-Term Oral Mifepristone for Central Serous Chorioretinopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02354170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*